ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P30-17 New Drug-Related Prior Authorization (PA) Criteria: Topical Retinoids
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 05, 2017
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2821 - 2830 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P41-18 Update: Change to TPA Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 04, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P46-17 Addition of Drug to the Self-Administered Oncology PA with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P12-18 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial Lines of Business - Effective June 4, 2018
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 02, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P10-18 Blue Cross Will Cease Mailing Certain Provider Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 01, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P19R1-17 New Remittance Code: OA-45 for Purchased/Referred (PRC)-Eligible Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 24, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P8-18 Changes to PA for Hip Arthroplasty, Hip Resurfacing and Knee Arthroplasty for Commercial and Government Programs Lines of Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P78-17 Cotiviti to Perform Inpatient Claims Reviews
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 12, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P54-17 Clarification to Commercial Prior Authorization Requirements for Early Intensive Behavioral Intervention (EIBI)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 10, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P23-18 Clinical Reviews for Court-Ordered Substance Use Disorder Treatment
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 01, 2018